Journal: Experimental and Therapeutic Medicine

Article Title: Triptolide inhibits vascular endothelial growth factor-mediated angiogenesis in human breast cancer cells

doi: 10.3892/etm.2018.6200

Figure Lengend Snippet: Triptolide inhibits endothelial tube formation and cell proliferation in vitro . (A) Representative images of the HUVEC tube formation assay after triptolide treatment (magnification, ×200). Cells treated with si-VEGFA group were used as a positive control. The results were quantified by measuring (B) branch points and (C) total tube length. BrdU incorporation assay (D) representative images (magnification, ×200) and (E) statistical analysis. *P<0.05 vs. the Con group; # P<0.05 vs. the NC group. HUVEC, human umbilical vein endothelial cell; VEGFA, vascular endothelial growth factor A; BrdU, bromodeoxyuridine; Con, control; NC, negative control; si-VEGFA, small interfering RNA targeting VEGFA.

Article Snippet: Cells were then processed for BrdU incorporation using a BrdU cell proliferation assay Kit (cat. no. K306-200; Biovision, Milpitas, CA, USA) according to the manufacturer's protocol, which has been described previously ( ).

Techniques: In Vitro, HUVEC Tube Formation Assay, Positive Control, BrdU Incorporation Assay, Negative Control, Small Interfering RNA

Journal: PLoS ONE

Article Title: Alpha-Catulin Contributes to Drug-Resistance of Melanoma by Activating NF-κB and AP-1

doi: 10.1371/journal.pone.0119402

Figure Lengend Snippet: ( A ) Stable infected Mel.7 cells (n.s., sh-catu2) were treated with 0, 5, 10 and 20 μg/ml cisplatin for 24 h and analyzed by Western blot with antibody against Ki67. α-Tubulin was used as a loading control and quantification was performed with BioRad software. ( B ) Mel.7 cells (n.s., sh-catu2) were treated with 20, 10, 5, or 0 μg/ml cisplatin for 48 h and BrdU assay was performed. Therefore, cells were stained with BrdU solution and antibodies against BrdU and HRP conjugated secondary antibody was detected at 450 nm using a multiplate reader. ( C ) Mel.7 cells (n.s., sh-catu2) were treated with 0 or 10 μg/ml cisplatin for 18 hours, fixed, stained with propidium-iodide solution and analysed for cell cycle distribution using flow cytometry. ( D ) Cells as in ( C ) were analysed using western blot with antibodies against p21 cip/waf and p53.

Article Snippet: After 24 hours cells were treated with 20, 10, or 5 μg/ml cisplatin or were left untreated and after 48 hours CytoSelect BrdU Cell Proliferation ELISA Kit (Cell Biolabs, Inc.) was used to determine cell proliferation.

Techniques: Infection, Western Blot, Control, Software, BrdU Staining, Staining, Flow Cytometry

Journal: Scientific Reports

Article Title: Lamprey Prohibitin2 Arrest G2/M Phase Transition of HeLa Cells through Down-regulating Expression and Phosphorylation Level of Cell Cycle Proteins

doi: 10.1038/s41598-018-22212-0

Figure Lengend Snippet: Effect of Lm-PHB2 on the cell cycle. The double staining with both APC-BrdU and PI for detection of G1/S and/or G2/M cell cycle alteration after HeLa cells treated with rLm-PHB2 protein and PBS treatment as control.

Article Snippet: Cell cycle detection kit and BrdU cell proliferation detection kit was purchased from KeyGEN BioTECH.

Techniques: Double Staining, Control

Journal: Oncotarget

Article Title: Long-term prognostic implications and therapeutic target role of hexokinase II in patients with nasopharyngeal carcinoma

doi: 10.18632/oncotarget.7116

Figure Lengend Snippet: Cells without any treatments were adopted as controls. ( A ) 3-BrOP reduces intracellular ATP concentration of NPC cells. ATP levels were determined using the ATPlite kit according to manufacturer's protocol (PerkinElmer, Boston, MA). ( B ) Growth inhibitory effect of 3-BrOP on NPC cells. The cell proliferation was detected by BrdU in different cell groups.

Article Snippet: BrdU assay was performed using the BrdU Cell Proliferation assay kit (Merck, Marmstadt, Germany) following the manufacturer's protocol.

Techniques: Concentration Assay